ClinicalTrials.gg
RecruitingNCT07168213Updated Mar 9, 2026

Comparison of Two SpO2 Targets With Two Different Oximeters - Impact on FiO2 During Nasal High Flow Oxygen Therapy

An interventional study of Manual FiO2 titration with Philips oximeter (SpO2 target 90%) and Manual FiO2 titration with Nonin oximeter (SpO2 target 90%) in Oxygen Delivery, Acute Respiratory Failure and High Flow Oxygen Therapy, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Laval University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.

Planned enrollment
34th of 66
30 · median 31
Started
2025
with 5 others
No phase
46 of 94
10 open now
Primary completion
2027-06
later than 21 of 28 live
Registered
91st of 94
by date
Lead sponsor
8 of 94
Laval University

Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 34th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 46 with no phase, reaches primary completion later than 21 of the 28 other live ones, and was the 91st registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Respiratory Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.

Read the detailed description

The oximeters evaluated will be the Nonin (Plymouth, MN) and the Philips (Eindhoven, Netherlands). Two SpO2 targets will be evaluated: 90% and 94%.

A total of four 10-minute periods will be performed in randomized order: Nonin 90, Nonin 94, Philips 90, and Philips 94.

At the end of each 10-minute period, arterial gas will be collected through the arterial catheter.

03

Conditions studied

  • Oxygen Delivery
  • Acute Respiratory Failure
  • High Flow Oxygen Therapy
  • Hypoxemic Acute Respiratory Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • Admiitted in intensive care unit
  • Presence of an arterial catheter
  • Ongoing on high flow nasal oxygen therapy with SpO2 between 88 and 100% with a FiO2 between 40 and 80% with the usual oximeter .

Exclusion criteria

Exclusion Criteria:

  • No SpO2 signal with oximeter in use
  • False nails or nail polish
  • Methemoglobinemia >0.015 on last available arterial gas
  • Patient in isolation (multi-resistant bacteria, C-Difficile, SARS-CoV-2 ...)
  • Expected to use another respiratory support within two hour of inclusion (NIV or mechanical ventilation)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Nonin oximeter with a 90% SpO2 target

    During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 90% of SpO2.

    Device: Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)

  • Experimental
    Philips oximeter with a 90% SpO2 target

    During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 90% of SpO2.

    Device: Manual FiO2 titration with Philips oximeter (SpO2 target 90%)

  • Experimental
    Nonin oximeter with a 94% SpO2 target

    During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 94% of SpO2.

    Device: Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)

  • Experimental
    Philips oximeter with a 94% SpO2 target

    During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 94% of SpO2.

    Device: Manual FiO2 titration with Philips oximeter (SpO2 target 94%)

Interventions

  • DeviceManual FiO2 titration with Philips oximeter (SpO2 target 90%)

    FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter

  • DeviceManual FiO2 titration with Nonin oximeter (SpO2 target 90%)

    FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter

  • DeviceManual FiO2 titration with Philips oximeter (SpO2 target 94%)

    FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter

  • DeviceManual FiO2 titration with Nonin oximeter (SpO2 target 94%)

    FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter

06

What researchers measure

Primary outcomes

  1. FiO2

    FiO2 at the end of each study period (last minute average) to reach SpO2 target to reach SpO2 target with specific oximeter

    Time frame: Mean FiO2 in the two last minute of each study period between minute 8 and 10

Secondary outcomes

  1. Difference between SpO2 and SaO2

    Difference (%) between SpO2 from each oximeter and SaO2 (% of SaO2 overestimation and underestimation for each oximeter)

    Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction

  2. High flow weaning criteria

    Percentage of patient whose average FiO2 level below 40%

    Time frame: Mean FiO2in the two last minute of each study period (between minute 8 and 10)

  3. Intensive care unit transfert criteria

    Percentage of patients whose average FiO2 level over 60%

    Time frame: Mean FiO2in the two last minute of each study period (between minute 8 and 10)

  4. Intubation criteria

    Percentage of patients whose average FiO2 level over 80%

    Time frame: Mean FiO2in the two last minute of each study period (between minute 8 and 10)

  5. Mean difference on oxymeter

    Mean (±SD) of the gaps between the different oximeters tested

    Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 20 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 11, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07168213
Lead sponsor
Laval University
Responsible party
François Lellouche (Principal Investigator, Laval University) — Principal investigator
First posted
Sep 11, 2025
Start date
Oct 21, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Francois Lellouche Principal Investigator
Contact
francois.lellouche@criucpq.ulaval.ca
418-656-8711 ext. 3572

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion